Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Mount Everest Climbers 'Poisoned' by Guides Prompting Mass Helicopter Rescues in $20 Million Insurance Fraud Scheme, Police Say - 22 new malaria treatments announced as drug resistance grows
- 3Feeling wonder every day improves our health. Here’s how to do it.
- 4Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands
- 5The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
- Merz visit highlights new strategic, and strained, Germany-Israel bond
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- Step by step instructions to Explore Assessment Ramifications of Disc Rates
- Vote In favor of Your Favored Kind Of Cheddar
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- 5 Advancement Developments in Biotechnology
- All that You Really want to Be aware of Dental Inserts Facilities
- ‘Extraordinary’ Iron Age war trumpet uncovered in England
